Aspen sale sets hearts racing

Aspen Pharmacare sold its Thrombosis Business in Europe to US drugmaker Mylan to warm the hearts of shareholders fretting over the group's R38 billion debt.
Published on: 

Aspen Pharmacare shareholders showed their relief at the group's decision to pay down its hefty debt of R38 billion, and sell its Thrombosis Business in Europe. News of the sale to US drug maker Mylon injected more than 8% into the share price, pushing it above levels not seen this year. The sale also signalled Aspen's intention to home in on the developing world and corner the emerging market for its anti-blood clot medicines. – Derek Alberts

By Derek Alberts

Shareholders have welcomed drugmaker Aspen Pharmacare's decision to sell down R640 million euros (about R12.7 billion) of debt by dispensing with its Thrombosis Business in Europe. News of the deal (Sept 8) to sell the European rights to American pharmaceutical company Mylan lifted Aspen's share price by more than 8% above the R145.00 mark.

Much to the relief of shareholders, the proceeds from the deal will cut away at Aspen's almost R40 billion debt.

___STEADY_PAYWALL___

Loading content, please wait...

Related Stories

No stories found.
BizNews
www.biznews.com